Morgan Stanley (NYSE:MS) analyst Jeffrey Hung maintained a Buy rating on Ultragenyx Pharmaceutical (NASDAQ:RARE) on Wednesday, setting a price target of $91, which is approximately 6.61% below the present share price of $97.44.
Hung expects Ultragenyx Pharmaceutical to post earnings per share (EPS) of $0.42 for the fourth quarter of 2020.
The current consensus among 12 TipRanks analysts is for a Strong Buy rating of shares in Ultragenyx Pharmaceutical, with an average price target of $101.
The analysts price targets range from a high of $121 to a low of $64.
In its latest earnings report, released on 06/30/2020, the company reported a quarterly revenue of $61.71 million and a net profit of -$63.06 million. The company's market cap is $5.9 billion.
According to TipRanks.com, Morgan Stanley analyst Jeffrey Hung is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 28.0% and a 54.84% success rate.
Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. Mepsevii is an intravenous, which is used for the treatment of Mucopolysaccharidosis VII. Crysvita is an antibody administered via subcutaneous injection used for the treatment of XLH. The company was founded by Emil D. Kakkis on April 22, 2010 and is headquartered in Novato, CA.